For pain doctor Mark Wallace, arthritis meant his hobby of competitive swimming was becoming too painful.
“Every stroke was like an ice pick in my shoulder,” said Wallace, chief of the division of pain medicine at UC San Diego. Cortisone shots relieved the pain for about a month, and then it would return.
For philanthropist Denny Sanford, even walking was too painful. He sought relief for his arthritis with a right knee replacement, but that didn’t work well. So to treat his other knee, he looked for an alternative.
Wallace and Sanford said they found that relief with stem cells; Wallace at UC San Diego using cells from his bone marrow, and Sanford at a clinic in Germany using cells from his fat tissue. Their cases — particularly Wallace’s — illustrate how the use of stem cells to relieve joint pain is becoming an accepted part of orthopedic medicine.
With millions of baby boomers experiencing the miseries of arthritis, the need is great and growing.
Scott Wolf, CEO and Director of Research of Grace Century comments: “Regenerative medicine is gradually becoming part of mainstream healthcare and it is only a matter of time until it becomes essential. So watch our projects in this space.”
Read the rest of the article here.
Grace Century dental stem cell storage project partner Provia Laboratories LLC has begun it’s acquisition push by acquiring Vault Biobank’s dental stem cell business’ client agreements and distribution agreements. Provia will now handle storage services for Vault’s current clients, along with supplying it’s own dental stem storage product “Store-A-Tooth” to future clients acquired via Vault’s distribution channels.
Adam Houtman, Chief Executive Officer of the Vault explains, “When selecting a firm to entrust our client’s valuable samples, we chose Provia precisely because of their investment into quality, the strength of their team, and specifically the investment they’ve made into their cGMP facility. We feel confident that our client’s samples will be in the best possible hands.”
Provia offers the only cGMP dental stem cell banking solution for consumers and operates under the FDA’s current good manufacturing practice (“cGMP”) guidelines for processing human cell and tissue products.
Howard Greenman, Provia CEO, said “We are so pleased to accept the Vault’s client’s into the Provia Biobank and to continue to work with the dental office partners that the Vault has setup to inform patients of this important technology. Provia is committed to making dental stem cell banking available to families all over the world and doing so with the best technology, under the highest quality and regulatory scrutiny. As the market for dental stem cell banking continues to develop, we continue to focus on offering the best service and working with partners to do so”.
Read the full press release here.
Health companies within the digital technology sector experienced significant funding support during Q2 of 2017.
According to an article on Fierce Healthcare, data from StartUp Health has indicated that investors sunk a total of $3.8 billion into digital projects within the healthcare and medical industries during Q2. This level of investor funding has not been seen since 2011 and represents an 81% increase in comparison to the same period one year ago.
Grace Century President and Director of Research Scott Wold said “the healthcare industry is finally starting to catch-up with other industries in terms of the embracement of digital technology, and the large increase in investor dollars being pumped into healthcare projects in 2017 is a clear indication of this trend.”
Read the full Fierce Healthcare article here.
MediXall Group, Inc., the medical network arm of Grace Century Electronic Medical Records (EMR) portfolio partner Quantum, has announced that its program to recruit and enlist licensed and certified healthcare providers to its Member Network has attracted almost 1,500 registrants.
The MediXaid platform provides a B2C capability that brings together into a single, cloud-based, patent-pending virtual marketplace the consumers of healthcare products and services with providers that compete on price, location and schedule for requested products and services.
MediXall Group Chairman, Noel J. Guillama , stated, “When I envisioned the MediXaid platform I believed that healthcare would soon be moving toward the need to providing greater access, transparency and competition for the consumer and to ensuring a broader reach into a greater segment of the community for healthcare providers. Clearly, this vision has proven accurate and now even the federal government is calling for exactly what we are providing through the MediXaid platform and MediXall Group, Inc. The positive response we are seeing from the Providers we are contacting is exciting and serves to underscore that both the consumer and provider are seeing the need for a platform like MediXaid.”
Scott Wolf, President and Director of Research for Grace Century, commented “The speed of uptake from healthcare providers to the MediXall member program is very impressive. The numbers achieved to date are already 6 months ahead of MediXall member targets, and this is an excellent indicator of the future growth potential of the MediXaid platform.”
Read the full press release here
Stem cell therapy is often a “last resort” treatment for patients with end-stage heart diseases. A recent study, however, finds that the treatment could be more harmful than helpful if cardiac stem cells are involved.
Researchers found that using patients’ own cardiac stem cells to repair damaged heart tissue may not only be ineffective but that the stem cells may also develop inflammatory properties that cause further heart damage.
In the United States, around 5.7 million adults are living with heart failure. The condition occurs when the heart is no longer able to pump enough oxygen-rich blood to fulfill the body’s needs.
There is currently no cure for heart failure. In some cases, the condition can be managed through medication and lifestyle changes. For people with end-stage heart failure, however, there are limited treatment options.
Heart transplantation remains the primary treatment for end-stage heart failure, but there are not enough donor hearts to meet recipient needs. Figures from the Organ Transplantation and Procurement Network show that there are more than 3,900 patients in the U.S. waiting for a heart transplant. Last year, 3,191 heart transplants were performed.
Scott Wolf, CEO and Director of Research for Grace Century comments: “These research findings confirm the obvious fact: stem cells from the sick hearts are not good and unusable, hence, banking from a young healthy person is the only way to secure the future health.”
Read the rest of the article here.
The legal battle to get patients access to stem cell therapy in Texas is closer to reality, according to TWCNews.com latest news article.
Texas Governor Greg Abbott signed such legislation into law this week, and it means some patients will be heading into uncharted medical territory.
After Sept. 1, patients with terminal illnesses or severe chronic diseases will be allowed to access experimental stem cell treatments in Texas.
Currently, most patients who want stem cell therapy have to travel outside the United States to do it, and stem cell re-injections are only allowed here within a 24-hour window.
“This is going to protect patient health, and provide for the treatments to be done here locally at home,” said Mike Byrom, the Chief Science Officer at Austin stem cell bank BioEden.
Byrom said the new law will keep patients in the country, and will provide renewed hope for those with serious ailments.
Scott Wolf, CEO and Director of Research of Grace Century commented: ”The recognition of Stem Cells treating aliments, and acceptance in Texas is cracking the flood gates open. Get the Insurance companies on board and it lights out!“
Read the rest of the article here.
We tend to associate Millennials with the proliferation of technology; however, all the key technology improvements that we are witnessing today were effectively developed during the life of the trailing edge Baby Boomers (1956 to 1966). We the “trailing-edge” are the technology generation.
Our children, Millennials, have taken to technology and the creation of applications, at a ferocious rate. Few have used, let alone remember, the typewriter; they are more familiar with the computer keyboard introduced while in grade school.
These Millennials are starting to enter the healthcare system en masse. The leading edge of the Millennials today are 37 years old. They don’t function well without technology and as they enter healthcare, along with their parent’s high healthcare consumption years, healthcare is facing an inflection point and technology is the only answer.
We see Millennials beginning to question everything… I suppose you might say that we taught them right! Millennials are used to sharing their profile information across multiple platforms by simply entering a password and clicking a button. For them, filling out a form in longhand is a foreign concept, though we do it at nearly every visit to a physician.
Quantum Innovations, Inc., is pleased to announce that it has been accepted in to the Palm Beach County Medical Society (PBCMS) as an Endorsed Partner. This status is reached only with the approval of the recommendation and vote by the Board of Directors of the distinguished, nearly 100-year-old processional society.
Noel J. Guillama, President of Quantum Innovations, Inc. commented, “we are honored to be associated with such distinguished and historical society as the Palm Beach County Medical Society. For nearly 100 years it has represented the professionals of our community. We are committing to provide new technology solutions and to help enrich the science of wellness. We thank the PBCMS for the opportunity to help.”
Tenna Wiles, CEO of the PBCMS noted “we are pleased to add Quantum Innovations, Inc. to the “Endorsed Partner” status. We know of Mr. Guillama’s dedication to the community and to helping providers find better solutions and challenges, in particular in the use of new technologies.”
Quantum Innovations announced that it will use this opportunity to advance the profile of its innovative PWeR 3.0 Electronic Medical Record and Practice Management Platform. PBCMS member physicians will receive reduced pricing and enhanced local support.
Click here to read more
Noel Guillama, CEO of Quantum Group, attended the exclusive, SALT conference in Las Vegas last week.
SALT is essentially the “who’s who” of thought leaders – speakers this year included the 47th Vice President of the United States Joe Biden, and former UK Prime Minister David Cameron – and the conference bring together the thought leaders in finance, investment, political and economic trends is the world. Over 1,800 thought leaders, public policy officials, business professionals, investors and money managers from over 42 countries and 6 continents attended.This was the second time Quantum was invited to SALT, and gave Quantum the opportunity to meet with major family offices, venture capital, private equity and sovereign wealth funds.
Quantum were able to have in-depth meetings with three new groups interested in healthcare and health information technology – both domestic and from Europe – plus they will have access to the proprietary attendees platform for another years.
SALT was a great opportunity for Quantum and one that they will continue to harvest as a growth opportunity for PWeR.
Click here to see the list of investors.
Click here to see the full list of speakers.
Grace Century dental stem cell storage technology partner Provia Labs have announced the launch of a valuable new resource – access to comprehensive library of stem cell material, specially allocated for stem cell researchers.
The library includes ready to ship mesenchymal stem cells (MSCs) from dental pulp (DPSC) found in human third molars or human exfoliated deciduous teeth, as well as from follicular tissue, adipose tissue, placental tissue, and umbilical cord tissue. Provia is currently developing inventory of MSCs from bone marrow, chorionic villi, and amniotic fluid.
Howard Greenman, CEO of Provia Laboratories, said “It is part of our mission to deliver quality products and services that accelerate the development of cellular therapies. Delivering high quality stem cell material to researchers fits right at the core of our mission.”
Read the full press release by clicking here.